Replies to post #3147 on Imprimis Pharmaceuticals Inc (IMMY)

[derkampfer]

Key takeaways Q2 CC CEO Mark "it's an exciting time""fantastic Q congratulations""turning the corner""move to $100M rev run rate""we are at 60% margins and grow to 70%""leading Opthomology co. in US""100% commission sales force (100 people) doubled"

They’re moving in the right direction. Add ETON and others and it all propels IMMYs bottom line.

Will be listening to Q3 CC closely.